Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 2,761 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Ezetimibe, Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more

Conditions: Intrahepatic Cholestasis of Pregnancy
Interventions: Volixibat, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 4 more

Conditions: Prodromal Symptoms, Prodromal Stage, Prodromal States, Psychosis
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 13 Years to 19 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Childhood Obesity
Interventions: Healthy Youth Living Program; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 12 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hyperhidrosis, Palmar Hyperhidrosis
Interventions: Dexmecamylamine HCl, Placebo; Drug · Other
Lead sponsor: Atacama Therapeutics; Industry
Eligibility: 16 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Traumatic Stress Disorder, Post Traumatic Stress Disorder, Trauma and Stressor Related Disorders, Mental Disorders, Exercise
Interventions: High Intensity Interval Training (HIIT), Waitlist; Behavioral · Other
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Postmenopausal
Interventions: Exercise, No exercise; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: HIV Infections
Interventions: Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine, Measles, mumps, and rubella virus vaccine, live; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 23 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 24
States / cities: Birmingham, Alabama • Alhambra, California • Long Beach, California + 17 more

Conditions: Burns
Interventions: MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY, Santyl; Device
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Osteosarcoma
Interventions: Sm-EDTMP, Autologous Stem Cell Infusion, External Beam Radiotherapy; Drug · Other · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 10 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: KP-1461; Drug
Lead sponsor: Koronis Pharmaceuticals.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 9
States / cities: Bradenton, Florida • Miami, Florida • West Palm Beach, Florida + 6 more

Conditions: Seriously Ill Hospitalized Patients
Interventions: Default Order, Accountable Justification, Standardized Usual Care; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1,208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Pasadena, California • Livonia, Michigan

Conditions: HIV, Vascular Diseases, Cardiovascular Diseases, Atherosclerosis, HIV Infections
Interventions: Combination antiretroviral therapy (cART), Pentoxifylline, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Crohn's Disease
Interventions: H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group, Placebo Group; Drug
Lead sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Hamden, Connecticut • Lighthouse PT, Florida • Orlando, Florida

Conditions: HIV Infections, Depression
Interventions: Bupropion, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: New York, New York

Conditions: AML, Adult Recurrent, MDS
Interventions: LYT-200, Venetoclax, Azacitidine, Decitabine; Drug
Lead sponsor: PureTech; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • Miami, Florida + 6 more

Conditions: Reactive Airways Disease (RAD)
Interventions: Levalbuterol HCl Inhalation Solution, Albuterol HCl Inhalation Solution; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: Up to 48 Months
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 32
States / cities: Little Rock, Arkansas • Corona, California • Englewood, California + 29 more

Conditions: Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
Interventions: AL58805, AL8326, Eribulin, Fulvestrant; Drug
Lead sponsor: Advenchen Pharmaceuticals, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Speech and Language Disorder, Cerebral Palsy, Hemiplegia, Hemiparesis
Interventions: Speech-language therapy (SLT), Modified constraint-induced movement therapy (mCIMT); Behavioral
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 15 Months to 7 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: COVID-19 Pneumonia
Interventions: PF-06650833, Matching Placebo; Drug
Lead sponsor: Giovanni Franchin, M.D, Ph.D; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: High-Intensity Interval Training Exercise Program; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma
Interventions: Dabrafenib, trametinib, Carboplatin, Vincristine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Months to 17 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: Orange, California • Washington D.C., District of Columbia • Miami, Florida + 7 more

Conditions: Neuroblastoma
Interventions: Hu3F8 With GM-CSF; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Human Immunodeficiency Virus Infections
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

HOPE TEAM - Clinical High Risk Group CBSST

Development of a Youth Healthy Living Program With Underserved Adolescents at Rochester Alternative Learning Center

Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Effects of a Short-term Exercise Intervention on Sleep in Women Exposed to Trauma: A Randomized Controlled Trial

Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women

Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs

Medihoney and Santyl for Burn Injuries

Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma

Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens

Comparing Optimized Models of Primary And Specialist Services for Palliative Care: Pilot Feasibility Trial

Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People

A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers

Effect of mCIMT Casting on Speech-language Outcomes in Children With Hemiparesis

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Attitudes and Beliefs and the Steps of HIV Care